Sigma-Aldrich signs exclusive distribution agreement with Roche
Following an exclusive distribution agreement, life science company Sigma-Aldrich will employ its sales, marketing and e-commerce expertise for the exclusive worldwide distribution of the Biochemical Reagents product portfolio from Roche.
The Roche portfolio includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications. Eric Green, executive vice president and president, Sigma-Aldrich Research, said the addition of the life science tools “supports our strategy to augment our portfolio with products that accelerate customer scientific research programs”.
“This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich’s expanded e-commerce and distribution networks,” added Paul Brown, head of Roche Molecular Diagnostics. “In addition, this will provide us the flexibility to devote more resources to our primary focus areas.”
Transition of the Roche portfolio to Sigma-Aldrich is expected to take place later this year. In the interim, the products will continue to be available through existing Roche channels.
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
CSIRO announces 300+ job cuts as part of restructure
CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...
Synchron raises $305m to advance brain–computer interfaces
Synchron's Stentrode BCI platform is billed as the world's first endovascular...
